Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - TNS1 |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - TNS1 | triple-receptor negative breast cancer | sensitive | Buparlisib + Infigratinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, triple-receptor negative breast cancer xenograft models harboring FGFR2-TNS1 demonstrated rapid and complete tumor regression when treated with the combination of Infigratinib (BGJ398) and Buparlisib (BKM120) (PMID: 29203461). | 29203461 | |
FGFR2 - TNS1 | triple-receptor negative breast cancer | sensitive | Infigratinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, triple-receptor negative breast cancer xenograft models harboring FGFR2-TNS1 demonstrated tumor regression when treated with Infigratinib (BGJ398) (PMID: 29203461). | 29203461 | |
FGFR2 - TNS1 | triple-receptor negative breast cancer | no benefit | Buparlisib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, triple-receptor negative breast cancer xenograft models harboring FGFR2-TNS1 demonstrated stable disease upon treatment with Buparlisib (BKM120), but also exhibited general toxicity (PMID: 29203461). | 29203461 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|